Nocturia Market

The need for a patient to get up at night on a regular basis to urinate is called Nocturia. To be considered as a nocturnal void, a period of sleep must precede and follow the urinary episode. This means that when identifying nocturia episodes, the first-morning void is ignored. In 2002, the International Continence Society (ICS) defined nocturia as “the complaint that the individual has to wake at night one or more times to void”. This term has since been widely debated, and it was changed in 2017 to “waking to pass urine during the main sleep period.”

Identification of the correct underlying pathophysiologic cause of nocturia in a given patient is required for effective treatment. Reduced nocturnal secretion of antidiuretic hormone may cause the syndrome of nocturnal polyuria, a common cause of nocturia in the elderly. Depending on the underlying cause of nocturia in the elderly, there are several treatment options available. Antidiuretics such as desmopressin can be taken to reduce the amount of urine produced.

Get a Free Sample Copy of the Report at:

DelveInsight’s “Nocturia Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Nocturia, historical and forecasted epidemiology as well as the Nocturia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Nocturia market report also covers emerging drugs, current treatment practices, Nocturia market size and share of the individual therapies, current and forecasted Nocturia Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Nocturia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Nocturia Market Key Facts

  • Nocturia is often identified as the most unpleasant of all urinary symptoms, as well as one of the most popular. It is estimated that it affects 50 million people in the United States, with 10 million actually diagnosed with nocturia (Leslie et al, 2021).
  • A retrospective modeling study was conducted by Weidlich et al. (2017), to estimate the prevalence-based cost of illness imposed by nocturia (≥2 nocturnal voids per night) in Germany, Sweden, and the UK in an average year. The findings of this study showed that in an average year, there are an estimated 12.5 and 8.6 million patients ≥20 years of age with nocturia in Germany and the UK, respectively.
  • The prevalence of nocturia rises with age. There is a trend for young women to have a higher prevalence than young men, which is changed later in life. By age 80, the majority of people will rise at least once per night to void (Bliwise et al., 2019).
  • Many people may be unaware that nocturia is a medical disorder that can be treated, or they may be ashamed or hesitant to disclose their symptoms, due to which it remains underreported, underdiagnosed, and undertreated, with many patients thinking it is a natural part of ageing (International Continence Society, 2017).

Key Benefits of Nocturia Market Report

  • Nocturia market report provides an in-depth analysis of Nocturia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.
  • The report will help in developing business strategies by understanding the Nocturia Market trends & developments, key players, and future market competition that will shape and drive the market in the upcoming years.
  • The report covers Nocturia market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
  • The report provides a detailed assessment of the Nocturia patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Get a Free Sample Copy of the Report at:

Nocturia Market

Nocturia market size is anticipated to increase during the study period owing to the increasing prevalent cases of diabetes, kidney diseases and old age population in the 7MM.

The Nocturia market outlook section of the report helps to build a detailed comprehension of the historic, current and forecasted Nocturia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of Nocturia market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Nocturia Epidemiology

The Nocturia epidemiology section covers insights about historical and current Nocturia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. It helps to recognize the causes of current and forecasted Nocturia epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Nocturia Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nocturia market or expected to get launched in the market during the study period. The analysis covers the Nocturia market by drug uptake; patient uptake by therapies; and sales of each drug.   

 Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Nocturia Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Nocturia market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Nocturia emerging therapies.

As of now the clinical development activity around Nocturia remains pretty scarce as not many companies are active with their pipeline with respect to this condition.

Nocturia Companies:

  • Wellesly Pharmaceuticals 
  • Sanwa Kagaku Kenkyusho
  • Kyorin Pharmaceutical
  • Vantia Therapeutics 

And many others. 

Nocturia Therapies covered in the report includes:

  • Nocturol
  • SK-1404
  • Fedovapagon (VA106483)

And many more.

Get a Free Sample Copy of the Report at:

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Nocturia Competitive Intelligence Analysis
  4. Nocturia Market Overview at a Glance
  5. Nocturia Disease Background and Overview
  6. Nocturia Patient Journey
  7. Nocturia Epidemiology and Patient Population
  8. Nocturia Treatment Algorithm, Current Treatment, and Medical Practices
  9. Nocturia Unmet Needs
  10. Key Endpoints of Nocturia Treatment
  11. Nocturia Marketed Products
  12. Nocturia Emerging Therapies
  13. Nocturia Seven Major Market Analysis
  14. Attribute Analysis
  15. Nocturia Market Outlook (7 major markets)
  16. Nocturia Access and Reimbursement Overview
  17. KOL Views on the Nocturia Market.
  18. Nocturia Market Drivers
  19. Nocturia Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get a Free Sample Copy of the Report at:

Latest Reports By DelveInsight:
Nocturia Epidemiology Forecast
DelveInsight’s Nocturia Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Nocturia in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Nocturia Pipeline Insights
Nocturia Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Nocturia market.

Electroencephelographs (EEG) Pipeline Insight
DelveInsight’s, “Electroencephelographs (EEG) Pipeline Insight and Competitive Landscape, 2020,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. The report provides a detailed study of the emerging Electroencephelographs devices along with competitive landscape to help better understand the emerging Electroencephelographs devices and also covers the present clinical development scenario and growth prospects across Electroencephelographs (EEG) market.

Bevacizumab Biosimilars Insight
DelveInsight’s, “Bevacizumab– Biosimilar Insight, 2020,” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in Bevacizumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Acute Pyelonephritis Market
DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Latest Healthcare Blogs By DelveInsight:

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Contact Info:
Shruti Thakur
DelveInsight Business Research
Email: [email protected]
Phone No: +91-9650213330
Connect With Us at:
LinkedIn | Facebook | Twitter
Healthcare Blog
Get a Free Sample Copy of the Report at: